The enormous upsurge of interest in immune-based treatments for cancer such as vaccines and immune checkpoint inhibitors, and increased understanding of the role of the tumor microenvironment in treatment response, collectively point to the need for immune-competent orthotopic models for pre-clinical testing of these new therapies. This paper demonstrates how to establish an orthotopic immune-competent rat model of pleural malignant mesothelioma. Monitoring disease progression in orthotopic models is confounded by the internal location of the tumors. To longitudinally monitor disease progression and its effect on circulating immune cells in this and other rat models of cancer, a single tube flow cytometry assay requiring only 25 µl whole blood is described. This provides accurate quantification of seven immune parameters: total lymphocytes, monocytes and neutrophils, as well as the T-cell subsets CD4 and CD8, B-cells and Natural Killer cells. Different subsets of these parameters are useful in different circumstances and models, with the neutrophil to lymphocyte ratio having the greatest utility for monitoring disease progression in the mesothelioma model. Analyzing circulating immune cell levels using this single tube method may also assist in monitoring the response to immune-based treatments and understanding the underlying mechanisms leading to success or failure of treatment.
Introduction
Malignant mesothelioma (MM) is an aggressive malignancy which arises from transformed cells in the membrane (mesothelium) that lines the lung and abdominal cavities, heart and internal reproductive organs, and is the most common primary tumor of the lung cavity or pleura 1, 2 . Exposure to asbestos fibres accounts for 80% of all MM, and while bans on asbestos use were introduced decades ago in most western countries, its widespread use in the community has left a deadly legacy. The World Health Organization has estimated that 107,000 people worldwide die each year from asbestos related diseases, with mortality rates continuing to increase. A new non-occupational incidence wave is also emerging and there is little understanding of when, and at what level this will peak 3 .
The majority of people with MM are diagnosed late when systemic chemotherapy represents one of the only viable options 4 . The most effective chemotherapy and current 'standard of care' (pemetrexed together with cisplatin 5 ) was identified over 10 years ago. However failure of this treatment is inevitable and there are no proven second line options, leaving patients with a grim prognosis and median survival of only 12 months 2 . Therefore, there is an urgent unmet need for more effective treatments. Despite the examination of a number of novel therapies in clinical trials none has resulted in changes in practice. This is due in part to the low (5%) transference of pre-clinical results, generally performed in xenograft mouse models, to the clinical setting [6] [7] [8] . Such models do not faithfully recapitulate the complex aspects of the tumor microenvironment occurring in non-physiological locations, frequently in the absence of a functioning immune system 9 .
Syngeneic orthotopic models create a significantly more realistic tumor environment than the commonly used subcutaneous xenograft models as the tumors occur in the correct physiological location with an intact immune system 10, 11 . The larger size of the rat enhances its use as a rodent disease model, especially in drug studies where serial blood draws are required to assess treatment response and toxicity 12 . Furthermore, in models in which monitoring disease progression is difficult due to the location of the tumors (such as in the pleural cavity), the ability to monitor disease progression using factors found in the circulation is extremely attractive. The generation of a syngeneic orthotopic model of pleural mesothelioma using immune-competent rats is described. In addition, an easy and relatively non-invasive method for monitoring pleural disease progression by measuring circulating immune cells is also described.
1. Ensure the EDTA whole blood sample is well mixed by placing it on a slow rotary mixer for several min. Label one absolute counting tube for each sample. A pellet containing the beads should be visible underneath the metal bead holder at the bottom of the tube. 2. Transfer 25 µl of EDTA whole blood into a labelled absolute counting tube. The bead pellet will dissolve upon addition of the blood. 3. To each tube add 20 µl of anti-rat T/B/Natural Killer (NK) cell cocktail, 10 µl of anti-rat CD8a PE, 10 µl of anti-rat CD4 (domain 1) FITC and 10 µl of anti-rat CD45 PE/Cy7 ( Figure 4A ). Fluorophores are defined in Table 1 . 4. Centrifuge the tube briefly (300 x g) to ensure the antibodies and cells are in the bottom of the tube and not stuck to the side of the tube.
Vortex to mix and incubate for 15 min at RT. 5. To lyse red blood cells add 400 µl of 10 mM Tris, 0.15 M ammonium chloride buffer (pH 7.5) and vortex to mix. Lysis is complete when the sample appears translucent and not cloudy (Figures 4B and C) . Failure to lyse the sample completely will lead to increased background and falsely elevated counts when analyzing by flow cytometry.
Flow Cytometric Processing of Samples
Note: Perform on a 4 color flow cytometer.
1. Open the software in acquisition mode and a new template with 8 plots as depicted in Figure 5 .
2. Adjust instrument settings to those listed in Table 1 Figure 5Ai ) to count the fluorescent beads. The other gates are not as important at this acquisition stage but will be required for analysis. The absolute counting beads used in this protocol contain fluorescent dyes and can be detected in any channel although are weakest in the blue channel. 3. Using a prepared control blood sample, vortex and then load onto the cytometer and run at a low speed (12 µl/min) on setup mode so data acquisition gates can be adjusted. 4. Set the acquisition to collect 10,000 events in the R1 bead gate. 5. Set up a folder to record data and set file number and label sample file in acquisition menu. 6. Load the sample to be analyzed onto the cytometer and set the flow rate to medium (35 µl/min). Run each sample at the same flow rate. The flow rate may need to be varied to low (12 µl/min) or high (60 µl/min), but medium is generally appropriate. At this rate it takes approximately 90 to 120 sec to acquire 10,000 bead events for each sample. 7. Once the sample is loaded watch the scatter plots to make sure events are appearing in the R1 bead gate. Initially there can be some instability in the sample pressure causing drift in the scatter plots. Wait for this to stabilize. 8. Once stabilized, click on acquire and allow sample to run. Once the cytometer has finished acquiring 10,000 bead events in R1 the cytometer will stop acquiring and save all data. 9. Remove the sample and discard flow tube. The cytometer is now ready for the next sample. Run all samples and then proceed to analysis mode.
Immune Cell Analysis
Note: Gating strategies and Boolean algebra are used to define each cell population. Boolean algebra is a logic based analysis method that allows for multiple operations in a single definition. The analysis software of the flow cytometer (e.g., BD CELLQuest) allows for the use of Boolean algebra. The equations are used to actively account for the significant negative reactivity that assists in defining the cell to more specifically identify each cell population. 'Regions' are used to define a 'gate'. Regions define a 2 dimensional space whereas gates can be composed of numerous regions connected by algebraic operators (+, *,-, defined in Table 2 ).
1. Switch the software to analysis mode. An analysis template should be generated to match Figure 5 with the plots and gates shown. 2. Analyze each individual file (i.e., each individual sample) separately. Set up gates R1 through to R9 and then set up the algorithms for each cell type as defined in Table 2 (also shown in Figure 5 ) . 3. Use the cell statistics counter to calculate individual cell populations defined by gates and algorithms (Table 2 and Figure 5) . The algorithms will adjust cell numbers automatically in the cell statistics counter. 4. Calculate cell subsets using the following equation:
Note: Number of cell events counted (e.g., CD4 T cell events) is enumerated using the above equation to give cell number per µl of blood. Examples are shown in Figure 5 .
Representative Results
The method used in this paper for the generation of an orthotopic model of pleural mesothelioma using II-45 cells resulted in animals succumbing to mesothelioma in a reproducible and rapid timeframe, with no rats dying due to the implantation method. Titration of the number of cells implanted determined that 1x Blood was collected from rats approximately twice each week with no complications observed related to the collection. It is important to note that no more than 10% of the total blood volume (or approximately 2 ml) should be collected in a 2 week period. A flow cytometric assay which combined gating strategies and Boolean algebra was established to identify lymphocytes, monocytes and neutrophils and the lymphocyte subsets T, CD4 T, CD8 T, B and NK cells. The mean and range for each cell type was established using control rats (n=5) and was compared to the mean and range of II-45 implanted rats at endpoint (Table 3) . Endpoint values were first compared to determine whether differences existed in immune cell counts between healthy and diseased animals. In comparison to healthy control rats, total lymphocytes, CD4 T cells, B lymphocytes and NK cells decreased in II-45 implanted rats at endpoint whereas monocytes, neutrophils and neutrophil to lymphocyte ratio (NLR) increased.
To determine whether these immune cell parameters also changed with disease progression and thus could be used as surrogate markers for monitoring disease, longitudinal samples were also compared (Figure 7) . The most informative longitudinal parameter was NLR with increases detected up to 7 days before ethical endpoints ( Figure 7A ). For rats with high dose cells, high NLRs were detected between day 7 and day 12 post implantation, whereas for rats with low dose cells, the NLR began to increase between day 18 and 22. Total lymphocyte counts decreased with disease progression in rats with a longer disease time course model (low cell dose: 1 x10 4 , Figure 7B ). This decrease was not evident in rats with a rapid time course (high cell dose: 5 x10 
Discussion
This paper details a method for the generation of a rat syngeneic orthotopic model of pleural mesothelioma and a simple method for monitoring disease progression through longitudinal blood sampling.
The II-45 model was developed by exposing Fischer 344 rats to asbestos fibers 13 . Although this exposure represents the true dynamics of hostasbestos-immune system interactions for mesothelioma pathogenesis, it has a long lag time (taking years to generate) and can be dangerous for the researchers due to the potential exposure to asbestos fibers. Orthotopic implantation of II-45 cells into the pleural cavity of animals provides a safe and rapid model of cancer progression which mimics the human disease in an immune-competent host 11 . However the exact methods and principles to adhere to during these experimental procedures are not well defined. The procedure described results in a highly reproducible model that is relatively independent of the experience of the operator. The critical steps are 1, harvesting II-45 cells in the exponential growth phase and accurate counting of viable cells; 2, correct positioning of the implantation site and ensuring the needle does not penetrate too deeply and puncture the lungs or damage the heart, and 3, maintaining and monitoring the well-being of the animals.
The II-45 cell line is fast growing and requires passaging every 3 to 4 days in culture, therefore when preparing for implantation, cells should be sub-cultured and growth monitored daily. Cells should be harvested and counted when in the exponential growth phase, i.e., at approximately 70% confluence. Resuspension of cells in serum free media rather than PBS reduces the stress on the cells while counting and preparing for implantation. Accurate cell counts are crucial for reproducibility, especially when dosing with low cell numbers (e.g., 100 to 1,000). The suspension should be homogeneous and consist of single cells (no clumps). An implantation volume of 100 µl enables accurate dosing without impairing lung expansion through excessive fluid in the pleural cavity. The key steps at implantation are correct positioning and limiting the needle penetration to a depth of no more than 12 mm. Correct positioning of the needle at the injection site is extremely important to ensure that the cells are implanted into the pleural cavity and not into the peritoneal cavity. Incorrectly implanting cells too low can result in mesothelioma tumors growing through the diaphragm, into the liver and peritoneal cavity. Restricting the penetration depth of the needle is also extremely important to prevent mortality as a result of internal organ damage. This restriction can be achieved through the use of a spacer over a long needle (as shown) or the use of a shorter needle with a shaft length of 5 mm to 12 mm. In our hands, no adverse events have occurred during cell implantation. It is also essential to replace the needle after every implantation. Failure to do so can result in tumors growing out of the chest cavity along the injection line. Such growth outside of the pleural cavity is due to residual cells on the needle shaft and may result in extended survival.
In our hands this model has a 100% tumor engraftment rate when administering ≥ 1 x 10 3 cells. Disease progression in the II-45 mesothelioma model is quite rapid, being less than 40 days when 1 x 10 4 cells are implanted and less than 20 days for a dose of 5 x 10 5 cells. This may limit the usefulness of this model for pre-clinical testing of some therapies. The II-45 cells, while not commercially available can be sourced with permission from the originator 13 . However, the same implantation techniques and principles may also be applied to other rat mesothelioma cell lines available from cell line repositories when matched with the relevant syngeneic rat strains. The optimal cell dose may vary with cell line and would need to be determined for each line.
Monitoring disease progression and the well-being of the animals is difficult as the tumors are internal and cannot be monitored by size. Therefore we sought to develop a method of monitoring the animals that could predict deterioration of their condition such as an increase in NLR or other change in immune cell markers before physical symptoms became visible. The blood screen developed uses only 25 µl of peripheral blood so that regular sampling can be performed with minimal distress to the animal. The sampling technique described requires practice to gain the necessary expertise. However, once mastered it is fast and minimally invasive.
A critical step in the blood analysis is to prevent clotting of the blood sample by rapid transfer to an EDTA tube. Clotted samples should be discarded as the counts will be inaccurate. Another critical step is the red cell lysis prior to cell analysis. If the red cells are not fully lysed, the increased background will falsely elevate the counts. While the initial setup of dot plots and gating is time consuming, once the settings and template are saved, the assay requires little adjustment. The gating strategy employed uses a multi-parameter Boolean algebraic approach to deconvolute the data. By using known combinations of exclusive and shared antigens the algorithms for each line of the gate strategy define the discrete cell type in this six-dimensional data matrix 14 . This coupled with established accuracy of the ratiometric bead-based technology [15] [16] [17] has the advantage of enabling the enumeration of any defined cell type as both a proportion of cells and an absolute count per µl.
It is becoming increasingly recognized that the immune system plays an important role in the pathogenesis of cancer 18 . Both the failure of the immune system to recognize and destroy malignant cells and the suppression of immune cells by tumors can lead to uncontrolled tumor growth. Thus, the inclusion of an immune-competent tumor microenvironment is a critical consideration when modelling cancer and is a major advantage of syngeneic cancer models. These immune-competent models create a realistic and clinically relevant environment for tumor growth and immune interaction, which is deficient in xenogeneic models.
The immune parameters identified in this study that accompanied disease progression, i.e., lymphocyte counts, monocyte counts and the NLR, have also been shown to correlate with poor prognosis in human mesothelioma [19] [20] [21] providing evidence for the relevance of the model and the blood test. In the models presented, the clinical utility of monitoring the immune parameters increased with the longer time course (lower dose) and may be further improved by more frequent sampling at later stages of the disease. While this paper focuses on a model of mesothelioma, the ability to monitor tumor progression through peripheral blood sampling can be utilized for all syngeneic cancer models. Further, the assay can also be used to assess the immunological response to different therapies. Previously we have used this assay to monitor the response to an anti-cancer vaccine therapy in a syngeneic glioma model (9L) 22 . In that study, CD4 and CD8 T cells were the most informative markers. We have also used this assay and the II-45 mesothelioma model to identify differences in the immune response to tumors resistant to different chemotherapeutics 11 . In that study, all parameters except CD8 T cells showed significant differences. The longitudinal monitoring during disease progression described here highlights the potential of different immune cell parameters to correlate with cancer progression and the well-being of animals when undertaking syngeneic orthotopic modelling of cancer in rats.
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